若年性黄斑変性治療の世界市場レポート 2025年

若年性黄斑変性治療市場規模は、今後数年間で力強い成長が見込まれます。2029年の年間平均成長率（CAGR）は8.0%で、18億8,000万米ドルに成長します。予測期間中の成長は、高齢者人口の増加、眼科バイオテクノロジー新興企業の増加、標的ドラッグデリバリーシステムへの重点化、臨床試験件数の増加、遺伝子治療への投資拡大などの要因によるものと考えられます。この期間の主な動向としては、遺伝子検査の進歩、遺伝子治療の開発、幹細胞研究の進展、革新的治療に対する規制当局の支援、個別化医療アプローチの採用などが挙げられます。

網膜障害の有病率の増加は、今後数年間の若年性黄斑変性治療市場の拡大を牽引すると予想されます。眼球の光感受性層に影響を及ぼし、視力障害や視力喪失につながる網膜障害は、特に糖尿病や、網膜を徐々に損傷する糖尿病網膜症などの疾患の増加により、より一般的になりつつあります。若年性黄斑変性症の治療は、特に若い患者の早期介入によって視力を維持し、これらの網膜疾患を管理する上で不可欠です。例えば、Retina Australiaの2024年11月の報告書によると、オーストラリアでは約1万9,000人、つまり1,380人に1人が遺伝性網膜疾患（IRD）を患っていると推定されています。また、国立眼科研究所は、進行性加齢黄斑変性症（AMD）を患うアメリカ人の数は、2030年までに210万人から370万人に増加すると予測しています。これらの統計は、若年性黄斑変性治療に対するニーズの高まりが市場成長の原動力となっていることを裏付けています。

若年性黄斑変性治療市場の企業は、遺伝子治療のデリバリーと治療成績を改善するために、デュアルAAV（アデノ随伴ウイルス）ベクターなどの最先端の遺伝子治療に注力しています。デュアルAAVベクターは、2つのAAVベクターを利用し、1つのAAVの能力を超える大きな治療用遺伝子を導入することで、遺伝子治療をより効果的なものにします。例えば、2025年3月、スペインを拠点とするバイオテクノロジー企業SpliceBio社は、SB-007の第1/2相ASTRA試験で最初の患者投与を発表しました。この二重AAVベクター遺伝子治療は、全長ABCA4タンパク質の発現を回復させることを目的としたもので、現在治療法が承認されていない若年性黄斑変性症の一種であるスターガルト病の治療法となる可能性があります。この画期的な治療法は、希少な網膜疾患の治療における大きな進歩です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界若年性黄斑変性治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の若年性黄斑変性治療市場：成長率分析
• 世界の若年性黄斑変性治療市場の実績：規模と成長, 2019-2024
• 世界の若年性黄斑変性治療市場の予測：規模と成長, 2024-2029, 2034F
• 世界若年性黄斑変性治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の若年性黄斑変性治療市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 滲出型加齢黄斑変性
• ドライ型加齢黄斑変性
• 世界の若年性黄斑変性治療市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• デバイス
• 薬物
• 手術
• 世界の若年性黄斑変性治療市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 視力の維持
• 疾病管理
• 症状の緩和
• 予防ケア
• 臨床試験
• 世界の若年性黄斑変性治療市場：販売チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 外来手術センター
• その他の販売チャネル
• 世界の若年性黄斑変性治療市場滲出型加齢黄斑変性症の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 抗血管内皮増殖因子（抗VEGF）療法
• 光線力学療法（PDT）
• レーザー療法
• 世界の若年性黄斑変性治療市場、ドライ型加齢黄斑変性症のタイプ別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 栄養補助食品
• 遺伝子治療
• 幹細胞療法

第7章 地域別・国別分析

• 世界の若年性黄斑変性治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の若年性黄斑変性治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 若年性黄斑変性治療市場：競合情勢
• 若年性黄斑変性治療市場：企業プロファイル
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Regeneron Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Astellas Pharma Inc.
• Biogen Inc.
• Santen Pharmaceutical Co. Ltd.
• Teva Pharmaceutical Industries Ltd.
• Samsung Bioepis Co. Ltd.
• Spark Therapeutics Inc.
• Polpharma Biologics S.A.
• OrCam Technologies Ltd.
• Alkeus Pharmaceuticals Inc.
• Bioeq AG
• NuEyes Technologies Inc.
• Coherus BioSciences Inc.
• eSight Eyewear Inc.
• MeiraGTx Holdings plc
• Kubota Pharmaceutical Holdings Co. Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 若年性黄斑変性治療市場2029：新たな機会を提供する国
• 若年性黄斑変性治療市場2029：新たな機会を提供するセグメント
• 若年性黄斑変性治療市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Juvenile macular degeneration (Stargardt disease) treatment involves various approaches aimed at managing vision loss and enhancing the quality of life for individuals affected by this genetic eye condition. It is caused by genetic mutations that damage the macula, the central part of the retina, leading to gradual vision deterioration and difficulties with tasks such as reading and facial recognition.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary types of juvenile macular degeneration treatment are wet age-related macular degeneration and dry age-related macular degeneration. Wet age-related macular degeneration refers to a condition in which abnormal blood vessels form beneath the retina, causing fluid or blood leakage and rapid central vision loss. Treatments for juvenile macular degeneration include devices, medications, and surgery. These treatments focus on vision preservation, disease management, symptom relief, preventive care, and participation in clinical trials. They are provided through various channels such as hospitals, ambulatory surgical centers, and other healthcare settings.

The juvenile macular degeneration treatment market research report is one of a series of new reports from The Business Research Company that provides juvenile macular degeneration treatment market statistics, including the juvenile macular degeneration treatment industry global market size, regional shares, competitors with the juvenile macular degeneration treatment market share, detailed juvenile macular degeneration treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the juvenile macular degeneration treatment industry. These juvenile macular degeneration treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The juvenile macular degeneration treatment market size has grown strongly in recent years. It will grow from$1.28 billion in 2024 to $1.39 billion in 2025 at a compound annual growth rate (CAGR) of 8.2%. The growth during the historic period can be attributed to several factors, including the rising prevalence of genetic eye disorders, increased investment in ophthalmic research, a growing focus on pediatric eye care, the increasing prevalence of vision impairment among children, and the expanding integration of artificial intelligence in eye care diagnostics.

The juvenile macular degeneration treatment market size is expected to see strong growth in the next few years. It will grow to$1.88 billion in 2029 at a compound annual growth rate (CAGR) of 8.0%. The growth during the forecast period can be attributed to factors such as the growing geriatric population, an increase in ophthalmic biotechnology startups, a stronger focus on targeted drug delivery systems, a rise in the number of clinical trials, and greater investment in gene therapy. Key trends during this period include advancements in genetic testing, the development of gene therapies, progress in stem cell research, regulatory support for innovative treatments, and the adoption of personalized medicine approaches.

The growing prevalence of retinal disorders is expected to drive the expansion of the juvenile macular degeneration treatment market in the coming years. Retinal disorders, which affect the light-sensitive layer of the eye and lead to vision impairment or loss, are becoming more prevalent, particularly due to the rise in diabetes and conditions such as diabetic retinopathy, which gradually damages the retina. Juvenile macular degeneration treatments are essential in managing these retinal conditions by preserving vision through early intervention, particularly for young patients. For example, a November 2024 report from Retina Australia estimates that approximately 19,000 individuals in Australia, or 1 in 1,380 people, live with inherited retinal diseases (IRDs). Additionally, the National Eye Institute predicts that the number of Americans with advanced age-related macular degeneration (AMD) will grow from 2.1 million to 3.7 million by 2030. These statistics underline the increasing need for juvenile macular degeneration treatments, driving market growth.

Companies in the juvenile macular degeneration treatment market are focusing on cutting-edge gene therapies, such as dual adeno-associated viral (AAV) vectors, to improve gene therapy delivery and treatment outcomes. Dual AAV vectors utilize two AAV vectors to deliver large therapeutic genes that exceed the capacity of a single AAV, making gene therapy more effective. For instance, in March 2025, SpliceBio, a Spain-based biotechnology company, announced the first patient dosing in its Phase 1/2 ASTRA study for SB-007. This dual AAV vector gene therapy aims to restore full-length ABCA4 protein expression and could offer a potential treatment for Stargardt disease, a form of juvenile macular degeneration that currently has no approved treatments. This breakthrough represents a significant advancement in treating rare retinal diseases.

In July 2023, Astellas Pharma Inc., a Japan-based pharmaceutical company, acquired IVERIC Bio Inc., a US-based company specializing in juvenile macular degeneration treatments, particularly for Stargardt disease. Through this acquisition, Astellas aims to enhance its ophthalmology portfolio, accelerate the development of innovative treatments for retinal diseases, and expand its expertise in gene therapy and complement inhibition. This acquisition strengthens Astellas' position in the juvenile macular degeneration treatment market, positioning it to offer novel solutions for conditions such as Stargardt disease and geographic atrophy.

Major players in the juvenile macular degeneration treatment market are F. Hoffmann-La Roche Ltd., Bayer AG, Novartis AG, AbbVie Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Biogen Inc., Santen Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Samsung Bioepis Co. Ltd., Spark Therapeutics Inc., Polpharma Biologics S.A., OrCam Technologies Ltd., Alkeus Pharmaceuticals Inc., Bioeq AG, NuEyes Technologies Inc., Coherus BioSciences Inc., eSight Eyewear Inc., MeiraGTx Holdings plc, and Kubota Pharmaceutical Holdings Co. Ltd.

North America was the largest region in the juvenile macular degeneration treatment market in 2024. The regions covered in juvenile macular degeneration treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the juvenile macular degeneration treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The juvenile macular degeneration treatment market consists of revenues earned by entities by providing services such as vision therapy, low vision rehabilitation, genetic counseling, nutritional counseling, and psychological support for vision loss management. The market value includes the value of related goods sold by the service provider or included within the service offering. The juvenile macular degeneration (JMD) treatment market also includes sales of prescription eyewear, low vision aids, braille displays, specialty lighting devices, and dietary supplements for eye health. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Juvenile Macular Degeneration Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on juvenile macular degeneration treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for juvenile macular degeneration treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The juvenile macular degeneration treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Wet Age-Related Macular Degeneration; Dry Age-Related Macular Degeneration
• 2) By Treatment: Devices; Drugs; Surgery
• 3) By Application: Vision Preservation; Disease Management; Symptom Relief; Preventive Care; Clinical Trials
• 4) By Sales Channel: Hospitals; Ambulatory Surgical Centres; Other Sales Channel
• Subsegments:
• 1) By Wet Age-Related Macular Degeneration: Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapy; Photodynamic Therapy (PDT); Laser Therapy
• 2) By Dry Age-Related Macular Degeneration: Nutritional Supplements; Gene Therapy; Stem Cell Therapy
• Companies Mentioned: F. Hoffmann-La Roche Ltd.; Bayer AG; Novartis AG; AbbVie Inc.; Regeneron Pharmaceuticals Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Juvenile Macular Degeneration Treatment Market Characteristics

3. Juvenile Macular Degeneration Treatment Market Trends And Strategies

4. Juvenile Macular Degeneration Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Juvenile Macular Degeneration Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Juvenile Macular Degeneration Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Juvenile Macular Degeneration Treatment Market Growth Rate Analysis
• 5.4. Global Juvenile Macular Degeneration Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Juvenile Macular Degeneration Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Juvenile Macular Degeneration Treatment Total Addressable Market (TAM)

6. Juvenile Macular Degeneration Treatment Market Segmentation

• 6.1. Global Juvenile Macular Degeneration Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Wet Age-Related Macular Degeneration
• Dry Age-Related Macular Degeneration
• 6.2. Global Juvenile Macular Degeneration Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Devices
• Drugs
• Surgery
• 6.3. Global Juvenile Macular Degeneration Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Vision Preservation
• Disease Management
• Symptom Relief
• Preventive Care
• Clinical Trials
• 6.4. Global Juvenile Macular Degeneration Treatment Market, Segmentation By Sales Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Ambulatory Surgical Centres
• Other Sales Channel
• 6.5. Global Juvenile Macular Degeneration Treatment Market, Sub-Segmentation Of Wet Age-Related Macular Degeneration, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapy
• Photodynamic Therapy (PDT)
• Laser Therapy
• 6.6. Global Juvenile Macular Degeneration Treatment Market, Sub-Segmentation Of Dry Age-Related Macular Degeneration, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Nutritional Supplements
• Gene Therapy
• Stem Cell Therapy

7. Juvenile Macular Degeneration Treatment Market Regional And Country Analysis

• 7.1. Global Juvenile Macular Degeneration Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Juvenile Macular Degeneration Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Juvenile Macular Degeneration Treatment Market

• 8.1. Asia-Pacific Juvenile Macular Degeneration Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Juvenile Macular Degeneration Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Juvenile Macular Degeneration Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Juvenile Macular Degeneration Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Juvenile Macular Degeneration Treatment Market

• 9.1. China Juvenile Macular Degeneration Treatment Market Overview
• 9.2. China Juvenile Macular Degeneration Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Juvenile Macular Degeneration Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Juvenile Macular Degeneration Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Juvenile Macular Degeneration Treatment Market

• 10.1. India Juvenile Macular Degeneration Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Juvenile Macular Degeneration Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Juvenile Macular Degeneration Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Juvenile Macular Degeneration Treatment Market

• 11.1. Japan Juvenile Macular Degeneration Treatment Market Overview
• 11.2. Japan Juvenile Macular Degeneration Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Juvenile Macular Degeneration Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Juvenile Macular Degeneration Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Juvenile Macular Degeneration Treatment Market

• 12.1. Australia Juvenile Macular Degeneration Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Juvenile Macular Degeneration Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Juvenile Macular Degeneration Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Juvenile Macular Degeneration Treatment Market

• 13.1. Indonesia Juvenile Macular Degeneration Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Juvenile Macular Degeneration Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Juvenile Macular Degeneration Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Juvenile Macular Degeneration Treatment Market

• 14.1. South Korea Juvenile Macular Degeneration Treatment Market Overview
• 14.2. South Korea Juvenile Macular Degeneration Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Juvenile Macular Degeneration Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Juvenile Macular Degeneration Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Juvenile Macular Degeneration Treatment Market

• 15.1. Western Europe Juvenile Macular Degeneration Treatment Market Overview
• 15.2. Western Europe Juvenile Macular Degeneration Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Juvenile Macular Degeneration Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Juvenile Macular Degeneration Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Juvenile Macular Degeneration Treatment Market

• 16.1. UK Juvenile Macular Degeneration Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Juvenile Macular Degeneration Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Juvenile Macular Degeneration Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Juvenile Macular Degeneration Treatment Market

• 17.1. Germany Juvenile Macular Degeneration Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Juvenile Macular Degeneration Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Juvenile Macular Degeneration Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Juvenile Macular Degeneration Treatment Market

• 18.1. France Juvenile Macular Degeneration Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Juvenile Macular Degeneration Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Juvenile Macular Degeneration Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Juvenile Macular Degeneration Treatment Market

• 19.1. Italy Juvenile Macular Degeneration Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Juvenile Macular Degeneration Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Juvenile Macular Degeneration Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Juvenile Macular Degeneration Treatment Market

• 20.1. Spain Juvenile Macular Degeneration Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Juvenile Macular Degeneration Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Juvenile Macular Degeneration Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Juvenile Macular Degeneration Treatment Market

• 21.1. Eastern Europe Juvenile Macular Degeneration Treatment Market Overview
• 21.2. Eastern Europe Juvenile Macular Degeneration Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Juvenile Macular Degeneration Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Juvenile Macular Degeneration Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Juvenile Macular Degeneration Treatment Market

• 22.1. Russia Juvenile Macular Degeneration Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Juvenile Macular Degeneration Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Juvenile Macular Degeneration Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Juvenile Macular Degeneration Treatment Market

• 23.1. North America Juvenile Macular Degeneration Treatment Market Overview
• 23.2. North America Juvenile Macular Degeneration Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Juvenile Macular Degeneration Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Juvenile Macular Degeneration Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Juvenile Macular Degeneration Treatment Market

• 24.1. USA Juvenile Macular Degeneration Treatment Market Overview
• 24.2. USA Juvenile Macular Degeneration Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Juvenile Macular Degeneration Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Juvenile Macular Degeneration Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Juvenile Macular Degeneration Treatment Market

• 25.1. Canada Juvenile Macular Degeneration Treatment Market Overview
• 25.2. Canada Juvenile Macular Degeneration Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Juvenile Macular Degeneration Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Juvenile Macular Degeneration Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Juvenile Macular Degeneration Treatment Market

• 26.1. South America Juvenile Macular Degeneration Treatment Market Overview
• 26.2. South America Juvenile Macular Degeneration Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Juvenile Macular Degeneration Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Juvenile Macular Degeneration Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Juvenile Macular Degeneration Treatment Market

• 27.1. Brazil Juvenile Macular Degeneration Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Juvenile Macular Degeneration Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Juvenile Macular Degeneration Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Juvenile Macular Degeneration Treatment Market

• 28.1. Middle East Juvenile Macular Degeneration Treatment Market Overview
• 28.2. Middle East Juvenile Macular Degeneration Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Juvenile Macular Degeneration Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Juvenile Macular Degeneration Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Juvenile Macular Degeneration Treatment Market

• 29.1. Africa Juvenile Macular Degeneration Treatment Market Overview
• 29.2. Africa Juvenile Macular Degeneration Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Juvenile Macular Degeneration Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Juvenile Macular Degeneration Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Juvenile Macular Degeneration Treatment Market Competitive Landscape And Company Profiles

• 30.1. Juvenile Macular Degeneration Treatment Market Competitive Landscape
• 30.2. Juvenile Macular Degeneration Treatment Market Company Profiles
  • 30.2.1. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Regeneron Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Juvenile Macular Degeneration Treatment Market Other Major And Innovative Companies

• 31.1. Astellas Pharma Inc.
• 31.2. Biogen Inc.
• 31.3. Santen Pharmaceutical Co. Ltd.
• 31.4. Teva Pharmaceutical Industries Ltd.
• 31.5. Samsung Bioepis Co. Ltd.
• 31.6. Spark Therapeutics Inc.
• 31.7. Polpharma Biologics S.A.
• 31.8. OrCam Technologies Ltd.
• 31.9. Alkeus Pharmaceuticals Inc.
• 31.10. Bioeq AG
• 31.11. NuEyes Technologies Inc.
• 31.12. Coherus BioSciences Inc.
• 31.13. eSight Eyewear Inc.
• 31.14. MeiraGTx Holdings plc
• 31.15. Kubota Pharmaceutical Holdings Co. Ltd.

32. Global Juvenile Macular Degeneration Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Juvenile Macular Degeneration Treatment Market

34. Recent Developments In The Juvenile Macular Degeneration Treatment Market

35. Juvenile Macular Degeneration Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Juvenile Macular Degeneration Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Juvenile Macular Degeneration Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Juvenile Macular Degeneration Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer
• 250617_r34885_Juvenile_Macular_Degeneration_Treatment_GMR_2025